Vancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant Staphylococcus aureus blood isolates in Turkey

BMC Infectious Diseases

Volkan Korten^1,14  Mutlu Hayran⁴  Halis Akalin⁸  Cüneyt Özakin⁵  Gaye Usluer^1,10  Filiz Aksit^1,11  Ayşe Willke Topçu^1,13  Devrim Öztürk Dündar⁶  Ata Nevzat Yalcin³  Güner Söyletir⁷  Dilara Ogunc¹  Zeynep Gülay⁹  Deniz Gür^1,12  Server Yagci²  Banu Sancak^1,12 

[1] Department of Medical Microbiology, Akdeniz University Medical School, Antalya, Turkey;Department of Microbiology and Clinical Microbiology, Keciören Training and Research Hospital, Ankara, Turkey;Department of Infectious Diseases and Clinical Microbiology, Akdeniz University Medical School, Antalya, Turkey;Department of Preventive Oncology, Hacettepe University Oncology Institute, Ankara, Turkey;Department of Medical Microbiology, Uludag University Medical School, Bursa, Turkey;Department of Medical Microbiology, Kocaeli University Medical School, Kocaeli, Turkey;Department of Medical Microbiology, Marmara University Medical School, Istanbul, Turkey;Department of Infectious Diseases and Clinical Microbiology, Uludag University Medical School, Bursa, Turkey;Department of Medical Microbiology, Dokuz Eylul University Medical School, Izmir, Turkey;Department of Infectious Diseases and Clinical Microbiology, Osman Gazi University Medical School, Eskişehir, Turkey;Department of Medical Microbiology, Osman Gazi University Medical School, Eskişehir, Turkey;Department of Medical Microbiology, Hacettepe University Faculty of Medicine, Ankara, Turkey;Department of Infectious Diseases and Clinical Microbiology, Kocaeli University Medical School, Kocaeli, Turkey;Department of Infectious Diseases and Clinical Microbiology, Marmara University Medical School, Istanbul, Turkey

关键词: Blood isolates;    MRSA;    Heteroresistance;    MIC;    Daptomycin;    Vancomycin;   

Others  :  1145314
DOI  :  10.1186/1471-2334-13-583

 received in 2013-06-30, accepted in 2013-12-04,  发布年份 2013

【 摘 要 】

Background

The aim of this study was to determine the distribution of vancomycin and daptomycin MICs among methicillin-resistant Staphylococcus aureus (MRSA) blood isolates, the prevalence of heterogeneous vancomycin-intermediate S. aureus (hVISA) and the relationship between hVISA and vancomycin MIC values.

Methods

A total of 175 MRSA blood isolates were collected from seven university hospitals in Turkey. All isolates were tested for susceptibility to vancomycin and daptomycin by reference broth microdilution (BMD) and by standard Etest method. BMD test was performed according to CLSI guidelines and Etest was performed according to the instructions of the manufacturer. All isolates were screened for the presence of the hVISA by using macro Etest (MET) and population analysis profile-area under the curve (PAP-AUC) methods.

Results

The vancomycin MIC₅₀, MIC₉₀ and MIC ranges were 1, 2, and 0.5-2 μg/ml, respectively, by both of BMD and Etest. The daptomycin MIC₅₀, MIC₉₀ and MIC ranges were 0.5, 1 and 0.125 -1 μg/ml by BMD and 0.25, 0.5 and 0.06-1 μg/ml by Etest, respectively. The vancomycin MIC for 40.6% (71/175) of the MRSA isolates tested was >1 μg/ml by BMD. No vancomycin and daptomycin resistance was found among MRSA isolates. Percent agreement of Etest MICs with BMD MICs within ±1 doubling dilution was 100% and 73.1% for vancomycin and daptomycin, respectively. The prevalence of hVISA among MRSA blood isolates was 13.7% (24/175) by PAP-AUC method. MET identified only 14 of the hVISA strains (sensitivity, 58.3%), and there were 12 strains identified as hVISA that were not subsequently confirmed by PAP-AUC (specificity, 92.1%).

Conclusions

Agreement between BMD and Etest MICs is high both for vancomycin and daptomycin. Daptomycin was found to be highly active against MRSA isolates including hVISA. A considerable number of isolates are determined as hVISA among blood isolates. As it is impractical to use the reference method (PAP-AUC) for large numbers of isolates, laboratory methods for rapid and accurate identification of hVISA need to be developed.

【 授权许可】

   
2013 Sancak et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Hsu DI, Hidayat LK, Quist R, Hindler J, Karlsson A, Yusof A, Wong-Beringer A: Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents 2008, 32(5):378-385.
• [2]Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, Stellrecht K: Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008, 52(9):3315-3320.
• [3]Adam HJ, Louie L, Watt C, Gravel D, Bryce E, Loeb M, Matlow A, McGeer A, Mulvey MR, Simor AE, et al.: Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995–2006. Antimicrob Agents Chemother 2010, 54(2):945-949.
• [4]Musta AC, Riederer K, Shemes S, Chase P, Jose J, Johnson LB, Khatib R: Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J Clin Microbiol 2009, 47(6):1640-1644.
• [5]Park KH, Kim ES, Kim HS, Park SJ, Bang KM, Park HJ, Park SY, Moon SM, Chong YP, Kim SH, et al.: Comparison of the clinical features, bacterial genotypes and outcomes of patients with bacteraemia due to heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-susceptible S. aureus. J Antimicrob Chemother 2012, 67(8):1843-1849.
• [6]Rybak MJ, Leonard SN, Rossi KL, Cheung CM, Sader HS, Jones RN: Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol 2008, 46(9):2950-2954.
• [7]Van Hal SJ, Wehrhahn MC, Barbagiannakos T, Mercer J, Chen D, Paterson DL, Gosbell IB: Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates. J Clin Microbiol 2011, 49(4):1489-1494.
• [8]Clinical and Laboratory Standards Institute: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically—Eighth Edition: Approved Standard M07-A8. PA, USA: CLSI, Wayne; 2009.
• [9]Carroll KC, Glanz BD, Borek AP, Burger C, Bhally HS, Henciak S, Flayhart D: Evaluation of the BD Phoenix automated microbiology system for identification and antimicrobial susceptibility testing of Enterobacteriaceae. J Clin Microbiol 2006, 44(10):3506-3509.
• [10]Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP: A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 2001, 47(4):399-403.
• [11]Wootton M, MacGowan AP, Walsh TR, Howe RA: A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J Clin Microbiol 2007, 45(2):329-332.
• [12]Edwards B, Milne K, Lawes T, Cook I, Robb A, Gould IM: Is vancomycin MIC "creep" method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010. J Clin Microbiol 2012, 50(2):318-325.
• [13]Kehrmann J, Kaase M, Szabados F, Gatermann SG, Buer J, Rath PM, Steinmann J: Vancomycin MIC creep in MRSA blood culture isolates from Germany: a regional problem? Eur J Clin Microbiol Infect Dis 2011, 30(5):677-683.
• [14]Steinkraus G, White R, Friedrich L: Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001–05. J Antimicrob Chemother 2007, 60(4):788-794.
• [15]Reynolds R, Hope R, Warner M, Macgowan AP, Livermore DM: Ellington MJ, on behalf of the BEWPoRS: Lack of upward creep of glycopeptide MICs for methicillin-resistant Staphylococcus aureus (MRSA) isolated in the UK and Ireland 2001–07. J Antimicrob Chemother 2012, 67(12):2912-2918.
• [16]Sader HS, Fey PD, Limaye AP, Madinger N, Pankey G, Rahal J, Rybak MJ, Snydman DR, Steed LL, Waites K: Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob Agents Chemother 2009, 53(10):4127-4132.
• [17]Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, Alamo D, Ortega M, Lopez J, Mensa J: Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008, 46(2):193-200.
• [18]Khatib R, Jose J, Musta A, Sharma M, Fakih MG, Johnson LB, Riederer K, Shemes S: Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2011, 66(7):1594-1599.
• [19]Van Hal SJ, Lodise TP, Paterson DL: The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012, 54(6):755-771.
• [20]Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML: Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010, 23(1):99-139.
• [21]Prakash V, Lewis JS 2nd, Jorgensen JH: Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob Agents Chemother 2008, 52(12):4528.
• [22]Sader HS, Rhomberg PR, Jones RN: Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009, 53(7):3162-3165.
• [23]Satola SW, Farley MM, Anderson KF, Patel JB: Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method. J Clin Microbiol 2011, 49(1):177-183.
• [24]Walsh TR, Bolmstrom A, Qwarnstrom A, Ho P, Wootton M, Howe RA, MacGowan AP, Diekema D: Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 2001, 39(7):2439-2444.
• [25]Sancak B, Ercis S, Menemenlioglu D, Colakoglu S, Hascelik G: Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital. J Antimicrob Chemother 2005, 56(3):519-523.
• [26]Lin SY, Chen TC, Chen FJ, Chen YH, Lin YI, Kristopher Siu L, Lu PL: Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan Medical Center. J Microbiol Immunol Infect 2012, 45(6):435-441.
• [27]Van Hal SJ, Paterson DL: Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother 2011, 55(1):405-410.
• [28]Maor Y, Rahav G, Belausov N, Ben-David D, Smollan G, Keller N: Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center. J Clin Microbiol 2007, 45(5):1511-1514.
• [29]Kirby A, Graham R, Williams NJ, Wootton M, Broughton CM, Alanazi M, Anson J, Neal TJ, Parry CM: Staphylococcus aureus with reduced glycopeptide susceptibility in Liverpool, UK. J Antimicrob Chemother 2010, 65(4):721-724.
• [30]Kelley PG, Gao W, Ward PB, Howden BP: Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. J Antimicrob Chemother 2011, 66(5):1057-1060.